Publication at Second Faculty of Medicine |
2016
Abstract
Administering drugs in the form of inhalers remains the preferred mode of treatment of chronic obstructive pulmonary disease, with the exception of peroral anti-inflammatory drugs, such as roflumilast or theophylline. A new development is administering ultra-long-acting drugs, either as monotherapy or in combinations, with the possibility of administering some drugs twice per day in cases when this is indicated.
Drug combinations are another current trend.